Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML

Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML

Occurrence of the BCR-ABL[superscript T315I] gatekeeper mutation is among the most pressing challenges in the therapy of chronic myeloid leukemia (CML). Several BCR-ABL inhibitors have multiple targets and pleiotropic effects that could be exploited for their synergistic potential. Testing combinati...

Full description

Bibliographic Details
Main Authors: Winter, Georg E (Author), Rix, Uwe (Author), Gleixner, Karoline V (Author), Grebien, Florian (Author), Gridling, Manuela (Author), Breitwieser, Florian P (Author), Bilban, Martin (Author), Colinge, Jacques (Author), Valent, Peter (Author), Bennett, Keiryn L (Author), Superti-Furga, Giulio (Author), Carlson, Scott M. (Contributor), White, Forest M. (Contributor), Muller, Andre C (Author)
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: Nature Publishing Group, 2014-08-26T12:05:55Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items